Compare Modine Manufacturing Company (MOD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs TG Therapeutics Inc — how do they compare? Modine Manufacturing Company trades at $247.12 (market cap $12.18B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Modine Manufacturing Company is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| MOD | TGTX | |
|---|---|---|
Market Cap | $12.18B | $8.26B |
Sector | Technology | Health |
52-Week High | $306.89 | $59.06 |
52-Week Low | $93.71 | $26.39 |
Enterprise Value | $12.54B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing Company (MOD) trades at $227.88, down 0.64% with a bearish technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and robust analyst support (76.9% buy ratings). However, elevated valuation ratios (P/E 101.48, EV/EBITDA 42.12) and declining projected profit margins for 2026 present challenges. Recent institutional buying and positive data center cooling demand provide growth catalysts.
MOD offers significant upside to the $328.80 consensus price target but faces valuation compression risks amid projected margin pressure. The stock's technical weakness near support at $223 requires monitoring, while institutional confidence and thermal management technology leadership support long-term prospects. Key risks include supply chain constraints and competitive threats in the data center cooling space.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
